· The CHMP positive opinion marks the first time a monoclonal antibody treatment for COVID-19 has received a recommendation for marketing authorisation from the EMA
· The recommendation is based on data from the global Phase III clinical trial investigating regdanvimab as a treatment for multiple variants of COVID-19, including the Delta variant
· Regdanvimab is the first authorised COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS); More than 21,366 people treated with regdanvimab in 127 hospitals in the Republic of Korea
INCHEON, Korea, Nov 15 (Bernama-BUSINESS WIRE) — Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.
- Live Updates: Israel Says It Killed Hezbollah Leader; Hezbollah Hasn’t Confirmed
- Uzbekistan, Egypt Set Up Joint Chamber Of Commerce
- Lebanon Violence Forces More Than 90,000 People From Their Homes: UN
- South African woman turns 118, among the oldest in the world
- Calcitrant Netanyahu Insists On Carrying Out Attacks In Lebanon, Threatens Iran
- U.S.-Led Coalition Mission In Iraq Drawing To End By Sept Next Year
- Pakistan Received 1.03 Billion USD From IMF: State Bank
- Ishiba Elected Japan’s Ruling Party Leader, To Become New PM
- QUAD Is Political, Diplomatic Tool For U.S. Uni-Polar Domination: DPRK Foreign Ministry
- Leaders At UNGA Gravely Concerned With Middle East Violence, Slam Israel For “Genocide”